Recent progress in the treatment of uveitic macular edema

References

• Sen HN, Vitale S, Gangaputra SS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology. 2014;121(11):2275–2286.
   PubMed Web of Science ®Google Scholar
• Zola M, Briamonte C, Lorenzi U, et al. Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone. Clin Ophthalmol. 2017;11:1949–1956.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Sala-Puigdollers A, Velazquez-Villoria D, et al. Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. PLoS ONE. 2019;14(1):e0209997.
   PubMed Web of Science ®Google Scholar
• Alba-Linero C, Sala Puigdollers A, Romero B, et al. Long-term intravitreal dexamethasone implant outcomes in Uveitis. Ocul Immunol Inflamm. 2019;17:1–10.
   Google Scholar
• Fardet DL, Kassar A, Cabane J, et al. Corticosteroid-induced adverse events in adults. Drug Saf. 2007;30:861–881.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for non infectious intermediate or posterior uveitis. Ozurdex HURON Study Group. Arch Ophthalmol. 2011 May;129(5):545–553. **.
   PubMed Web of Science ®Google Scholar
• Ratra E, Barh ABanerjee M et al. Safety and efficacy of intravitreal dexamethasone implant for refractory uveitic macular edema in adults and children. Ocul Inmunol Inflamm 2018;1-7
   Google Scholar
• Fonollosa A, Llorenç V, Artaraz J, et al. Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis. Retina. 2016;36(9):1778–1785.
   PubMed Web of Science ®Google Scholar
• Adán A, Pelegrín L, Rey A, et al. Dexamethasone intravitreal implant for treatement of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 2013;33(7):1435–1440.
   PubMed Web of Science ®Google Scholar
• Pelegrín L, de la Maza MS, Molins B, et al. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveítis. Eye (Lond). 2015;29(7):943–950.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versu fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–1926.
   PubMed Web of Science ®Google Scholar
• Weber LF, Marx S, Auffarth GU, et al. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect. 2019;9:3.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Lin P, Keenan RT, et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis. posterior uveitis and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940–1948.
   PubMed Web of Science ®Google Scholar
• Reddy AK, Burkholder BM, Khan IR, et al. Iluvien implantation for uveitis and uveitic macular edema. Ocul Immunol Inflamm. 2018;26(2):315–316.
   PubMed Web of Science ®Google Scholar
• Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132:794–796.
   PubMed Web of Science ®Google Scholar
• Jeon S, Lee WK, Jung Y. Changes in the intraocular cytokine levels after intravitreal bevacizumab in uveitic macular edema. Ocul Immunol Inflamm. 2012;20:360–364.
   PubMed Web of Science ®Google Scholar
• Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye. 2009;23:1812–1818.
   PubMed Web of Science ®Google Scholar
• Paroli MP, Teodori C, D’Alessandro M, et al. Increased vascular endothelial growth factor levels in aqueous humour and serum of patients with quiescent uveitis. Eur J Ophthalmol. 2007;17:938–942.
   PubMed Web of Science ®Google Scholar
• Hernandez Garfella ML, Palomares Fort P, Roman Ivorra JA, et al. Aqueous humor levels of different interleukins 1β, 2, 6 and 10, tumor necrosis factor-alpha and vascular endothelial growth factor in uveitis treated with adalimumab. J Ophthalmic Vis Res. 2015;10:49–54.
   PubMedGoogle Scholar
• Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574–9.e1.
   PubMed Web of Science ®Google Scholar
• Kozak I, Shoughy SS, Stone DU. Intravitreal antiangiogenic therapy of uveitic macular edema: a review. J Ocul Pharmacol Ther. 2017;33:235–239.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.
   PubMed Web of Science ®Google Scholar
• Mérida S, Palacios E, Navea A, et al. New immunosuppressive therapies in uveitis treatment. Int J Mol Sci. 2015;16(8):18778–18795.
   PubMed Web of Science ®Google Scholar
• Pacheco PA, Taylor SR, Cuchacovich MT, et al. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm. 2008;16(4):161–165.
   PubMed Web of Science ®Google Scholar
• Doycheva D, Zierhut M, Blumenstock G, et al. Mycophenolate mofetil in the therapy of uveitic macular edema – long-termresults. Ocul Immunol Inflamm. 2012;20(3):203–211.
   PubMed Web of Science ®Google Scholar
• Neri P, Mariotti C, Cimino L, et al. Long-term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil. Int Ophthalmol. 2008;29(3):127–133.
   PubMedGoogle Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–2198.
   PubMed Web of Science ®Google Scholar
• Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–584.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin a therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983;96(3):275–282.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol. 2009;3:559.
   PubMedGoogle Scholar
• Lewczuk N. Zdebik A and Boguslawska J. Interferon alpha 2a and 2b in ophthalmololgy: a review. J Interferon Cytokine Res. 2019.
   PubMedGoogle Scholar
• Deuter CM, Ko¨tter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–791.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Ko¨ Tter I, Gu¨naydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478–486.
   PubMed Web of Science ®Google Scholar
• De Simone L, Sangiovanni A, Aldigeri R, et al. Interferon Alpha-2a treatment for post-uveitic refractory macular edema. Ocul Immunol Inflamm. 2019;20:1–7.
   Google Scholar
• Oray M, Onal S, Uludag G, et al. Interferon alpha for the treatment of cystoid macular edema associated with presumed ocular tuberculosis. J Ocul Pharmacol Ther. 2017;33(4):304–312.
   PubMed Web of Science ®Google Scholar
• Qian Z, Fardeau C, Cardoso JN, et al. Effect of interferon a2a in cystoid macular edema due to intraocular infection. Eur J Ophthalmol. 2015;25:431–436.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kotter I, Gunaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913.
   PubMed Web of Science ®Google Scholar
• Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452.
   PubMed Web of Science ®Google Scholar
• Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634–1635.
   PubMed Web of Science ®Google Scholar
• Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322:547–549.
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–255.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis and panuveitis: a retrospective observational study of 107 patients. ClinRheumatol. 2019;38(2):407–415.
   Web of Science ®Google Scholar
• Lejoeux R, Diwo E, Vallet H, et al. Infliximab and Adalimumab in uveitic macular edema. Ocul Immunol Inflamm. 2018;26(7):991–996.
   PubMed Web of Science ®Google Scholar
• Maujmder PD, Yamuna G, Majumder AK, et al. A case of human leukocyte antigen B27- associated ocular hypotony successfully treated with Golimumab. Indian J Ophthalmol. 2018;66(7):1006–1008.
   PubMed Web of Science ®Google Scholar
• Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, et al. Off-label uses of anti-TNF therapy in three frequent disorders: behçet’s disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm. 2013;2013:1–10.
   Google Scholar
• Mesquida M, Hernández MV, Llorenç V, et al. Behçet disease-associated uveitis successfully treated with Golimumab. Ocul Inmmunol Inflammation. 2012;21(2):160–162.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Saraceno R, Chiricozzi A, et al. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013;7:339–348.
   PubMed Web of Science ®Google Scholar
• Dattola A, Cannizzaro MV, Mazzeo M, et al. Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: preliminary real-life data. Dermatol Ther (Heidelb). 2017;4:485–492.
   Google Scholar
• Llorenç V, Mesquida M, Sainz de la Maza M, et al. Certolizumab pegol, a new anti-TNF-α in the armamentarium against ocular inflammation. Ocul Immunol Inflamm. 2016;24(2):167–172.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Dcheuderle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmaco vigilance safety database. Arthritis Rheumatol. 2018;70(9):1399–1407.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Leszczynska A, Llorenç V, et al. Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol. 2014;176(3):301–309.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38(7):1361–1370.
   PubMed Web of Science ®Google Scholar
• Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefe’s Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632.
   PubMed Web of Science ®Google Scholar
• De la Maza MS, Llorenç V, Adán A, et al. Targeting interleukin-6 in autoimmune uveitis. Autoimmun Rev. 2017;16(10):1079–1089.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;2:215–220.
   Google Scholar
• Calvo-Río V, Blanco R, Santos-Gómez M, et al. Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review. Ocul Immunol Inflamm. 2016;1–6.
   Web of Science ®Google Scholar
• Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19(5):382–383.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380–2386.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the stop-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis. Am J Ophthalmol. 2017;187:71–80.
   Google Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85–94.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69:277e290.
   Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase 3 study. Arthritis Rheumatol. 2015;67:1424e–1437.
   PubMed Web of Science ®Google Scholar
• Karkanová M, Varona R, Soo Y, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2018;1–10.
   Web of Science ®Google Scholar
• Koronis S, Stavrakas P, Balidis M, et al. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667–680.
   PubMed Web of Science ®Google Scholar
• Wroblewski K, Sen HN, Yeh S, et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol. 2011;46(4):322–328.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840e847.
   Google Scholar
• Heiligenhaus A, Bornfeld N, Foerster MH, et al. Long-term results of pars plana vitrectomy in the management of complicated uveitis. Br J Ophthalmol. 1994;78:549–554.
   PubMed Web of Science ®Google Scholar
• Radetzky S, Walter P, Fauser S, et al. Visual outcome of patients with macular oedema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane. Graefes Arch Clin Exp Ophthalmol. 2004;242:273–278.
   PubMed Web of Science ®Google Scholar
• Androudi S, Ahmed M, Fiore T, et al. Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis. J Cataract Refract Surg. 2005;31:472–478.
   PubMed Web of Science ®Google Scholar
• Muhaya M, Calder VL, Towler HM, et al. Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man. Clin Exp Immunol. 1999;116(3):410–414.
   PubMed Web of Science ®Google Scholar
• Liversidge J, Dick A, Cheng YF, et al. RetinalCD5+ antigen specific lymphocytes, TCR-gamma delta T cells andB cells cultured from the vitreous in acute sympathetic ophthalmitis. Autoimmunity. 1993;15(4):257–266.
   PubMed Web of Science ®Google Scholar
• Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:24–31.
   PubMed Web of Science ®Google Scholar
• Paulus YM, Wong IG, Sanislo S, et al. Prefoveal vitreous condensation in chronic inflammation. Ophthalmic Surg Lasers Imaging Retina. 2014;45(5):447–450.
   PubMed Web of Science ®Google Scholar
• Henry CR, Becker MD, Yang Y, et al. Pars plana vitrectomy for the treatment of uveitis. Am J Ophthalmol. 2018;190:142–149.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with behçet’s disease uveitis: an international, randomized, double-masked, placebo controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26:1–11.
   PubMed Web of Science ®Google Scholar
• Tranos P, Scott R, Zambarakji H, et al. The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: arandomised, controlled pilot study. Br J Ophthalmol. 2006;90(9):1107–1110.
   PubMed Web of Science ®Google Scholar
• Becker MDavis J. 2005. Vitrectomy in the treatment of uveitis. American Journal Of Ophthalmology 140 (6):1096–1105. doi:10.1016/j.ajo.2005.07.017.
   PubMed Web of Science ®Google Scholar
• Gass JD, Norton EW. Follow-up study of cystoid macular edema following cataract extraction. Trans Am Acad Ophthalmol Otolaryngol. 1969;73:665–682.
   PubMedGoogle Scholar
• Accorinti M, Okada AA, Smith JR, et al. Epidemiology of macular edema in uveitis. Ocul Immunol Inflamm. 2019;27(2):169–180.
   PubMed Web of Science ®Google Scholar
• Iannetti L, Accorinti M, Liverani M, et al. Optical coherence tomography for classification and clinical evaluation of macular edema in patients with uveitis. Ocul Immunol Inflamm. 2008;16(4):155–160.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004;111(5):946–953.
   PubMed Web of Science ®Google Scholar
• Matas J, Llorenc¸ V, Fonollosa A, et al. Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis. PLoS ONE. 2019;14(1):e0210799.
   PubMed Web of Science ®Google Scholar
• Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–1449.
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MSA, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336.
   PubMed Web of Science ®Google Scholar